In the past, Cerner has called upon them for help in hospital security systems.
It wouldn't surprise me to wake up one day and see Cerner buy this company outright.
They have increased their expertise with the purchase of Delphis. Furthermore, their strong relationships with the largest medical centers in the U.S. is invaluable.
Stay tuned for some nice surprises.
UPDATE: Nokia Is On Track To Beat, JP Morgan Says
By Jayson Derrick 20 hours ago
In a report published Tuesday, JP Morgan analyst Sandeep Deshpande stated that Nokia Corporation (NYSE: NOK) remains a top pick as currency translation will aid EBIT – a fact that may be ignored in consensus estimates.
According to Deshpande, the dollar strength does not increase margins but absolute EBIT should increase. The analyst continued to say that consensus estimates does not reflect currency impacts, implying the company can exceed estimates.
"Because of balanced currency exposure Nokia will not benefit significantly from transactional margin gains from the shift of the euro," Deshpande wrote. "However as per the disclosed exposure in multiple currencies, Nokia EBIT should rise 13 percent year over year in 2015 (#$%$1840 million) even without underlying business growth."
The analyst said that the current consensus estimate is looking for #$%$1692 million non-IFRS EBIT for fiscal 2015. If the full translation impact was in fact seen in fiscal 2015, Nokia could exceed consensus estimates by 8.7 percent.
Desphande added that it is "difficult" to raise estimates to the full extent of the currency impact due to a certain degree of hedging. However, the analyst stated that currency benefits coupled with underlying growth implies the company is well position for the coming year.
Shares are Overweight rated with a $10.80 price target.
Pipeline coming to fruition and increased funding from gov't contracts.
Also, losses dropped significantly!
Good news in my eyes.
Don't know how you're looking at it.
Sentiment: Strong Buy
that's why AEMD price went up over 15% today.
Dept of Defense wants to start production as soon as possible.
Now we can look forward to monetizing our product....finally.
The Drugs That Cost 743 Percent More in 2014 Than 2013
By Everyday Health Editors
Published Mar 10, 2015
A new drug-trends report shows a 743 percent increase in the amount spent on hepatitis C drugs in the United States in 2014 compared with 2013.
You forgot to add in the $50 million in cash on hand now!
$2.83 per share
$50 million cash
negligible debt (only $2 million)
$100 million upfront payment
$283 million future payments
Yet market cap well under $200 million!
Buying the company here, dissolving it, you would make a quarter billion dollars!!!
Plus have their pipeline to boot!
Doesn't make sense
They now have $1.50 per share net in cash (without future $283 million in payments to be received).
You can buy the company and pay for it with its own cash !!!!!!!!!!!
they will focus on late stage projects,
cut expenses dramatically with the sale of Zohydro,
AND they have cut losses.
Can't possibly stay at these prices.
Sentiment: Strong Buy
I didn't see their name on the agenda.
Nor did I see any press releases regarding their attendance.
From the conference
Video shows an incredibly thin MacBook. Cook is now holding it up. “Can you even see it, I can’t even feel it!”
You get a sign stating that you really have one.......but you just can see it!
Gold is soaring in all currencies that are declining. However it dropping in US dollar terms because of the strengthening dollar. This despite worldwide buying by all central banks.
The same for Nokia. Stronger dollar means it takes fewer dollars to buy a share.
Quite simple really.
Should the dollar begin a collapse, you'll need more dollars to buy a share, and the of Nokia stock will soar.
My take.......go with their biggest competitor...Mylan Labs.
They've been trying to keep Zogenix out of this space all year.